Successful transendoscopic oesophageal mass ablation in two dogs with <i>Spirocerca lupi</i> associated oesophageal sarcoma

Yas, Einat; Kelmer, Gal; Shipov, Anna; Ben-Oz, Jennifer; Segev, Gil

doi:10.1111/jsap.12076

Cited by 15 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous report of two dogs with spirocercosis‐associated oesophageal neoplasia, transendoscopic oesophageal mass ablation using either laser or snare electrocautery had no complications, and hospitalisation time was short (1–2 days), and therefore, treatment cost was lower compared with open thoracic oesophageal surgery (Ranen and others 2004b, Yas and others 2013). The present study demonstrates that transendoscopic oesophageal mass ablation is feasible in most (80 per cent) cases and is associated with an acceptable complication rate.…”

Section: Discussionmentioning

confidence: 90%

“…Transendoscopic oesophageal mass ablation using laser and electrocautery was described in two dogs with spirocercosis‐associated oesophageal neoplasia (Yas and others 2013). Due to the limited number of cases, robust conclusions regarding the procedure's complication rate and long‐term outcome, especially in comparison to open‐chest oesophageal surgery, cannot be made.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Long‐term outcome of transendoscopic oesophageal mass ablation in dogs with Spirocerca lupi ‐associated oesophageal sarcoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

Oesophageal sarcoma is a potential sequel of Spirocerca lupi infection. Oesophageal mass excision can be performed by open chest surgery. The objectives of this observational study were to evaluate the feasibility, short-term morbidity and long-term outcome of transendoscopic oesophageal mass ablation in dogs with spirocercosis-associated oesophageal neoplasia. A 9 mm video-endoscope and laser or electrocauterisation were used to debulk the oesophageal mass. Long-term follow-up was done by telephonic interviews. Fifteen dogs were included. The median tumour size was 5 cm (range 3.5-9). The median procedure time was 75 minutes (range 35-165) and was deemed successful in 12/15 dogs (80 per cent). Recovery was uneventful in all dogs. Immediate complications included oesophageal damage (two dogs) oesophageal perforation (one dog) and a focal thermal damage (one dog). The median hospitalisation time of all dogs was less than one day, with all but two discharged on the procedure day. The median survival time, available in nine dogs that were followed, was 202 days (range 51-691). Four of these dogs (44 per cent) survived more than six months, of which three survived more than one year. In conclusion, transendoscopic oesophageal mass ablation might be considered an alternative, palliative procedure for open-chest oesophageal surgery. It has comparable long-term survival, lower morbidity, short hospitalisation time and relatively low cost.

show abstract

Section: Discussionmentioning

confidence: 90%

mentioning

confidence: 99%

Long‐term outcome of transendoscopic oesophageal mass ablation in dogs with Spirocerca lupi ‐associated oesophageal sarcoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Visceral osteosarcoma secondary to retained surgical sponges has been reported in dogs [65,106], as has a case of osteosarcoma at the site of a previous subcutaneous injection [107]. Several cases of esophageal osteosarcoma are reported in dogs secondary to infection with the nematode parasite Spirocerca lupi [108,109,110,111]. There is a case report of orbital osteosarcoma in a cat, several years after enucleation for ocular melanoma, secondary to retention of conjunctival epithelium leading to cyst formation [24].…”

Section: Risks From Increased Cell Division/turnovermentioning

confidence: 99%

Risk Factors for Development of Canine and Human Osteosarcoma: A Comparative Review

Makielski

Mills

Sarver

et al. 2019

Veterinary Sciences

View full text Add to dashboard Cite

Osteosarcoma is the most common primary tumor of bone. Osteosarcomas are rare in humans, but occur more commonly in dogs. A comparative approach to studying osteosarcoma has highlighted many clinical and biologic aspects of the disease that are similar between dogs and humans; however, important species-specific differences are becoming increasingly recognized. In this review, we describe risk factors for the development of osteosarcoma in dogs and humans, including height and body size, genetics, and conditions that increase turnover of bone-forming cells, underscoring the concept that stochastic mutational events associated with cellular replication are likely to be the major molecular drivers of this disease. We also discuss adaptive, cancer-protective traits that have evolved in large, long-lived mammals, and how increasing size and longevity in the absence of natural selection can account for the elevated bone cancer risk in modern domestic dogs.

show abstract

“…The procedure is considered invasive, costly, painful and is associated with prolonged hospitalisation. Recently, transendoscopic oesophageal mass ablation was described as a new mode of therapy (Yas et al, 2013;Shipov et al, 2015). Removal or debulking of the neoplasia was performed using a 9 mm video-endoscope and laser or electrocauterisation.…”

mentioning

confidence: 99%

Spirocerca lupi induced oesophageal neoplasia: Predictors of surgical outcome

Pazzi

Kavkovsky

Shipov

et al. 2018

Veterinary Parasitology

View full text Add to dashboard Cite

Canine spirocercosis is caused by the nematode Spirocerca lupi. Migration results in oesophageal fibro-inflammatory nodules that may undergo neoplastic transformation. No studies have assessed pre- or post-surgical prognostic indicators in dogs that undergo intervention for S. lupi induced oesophageal neoplasia. This observational, multi-center study aimed to assess the outcome of dogs with Spirocerca induced sarcoma undergoing endoscopic-guided ablation (n = 12) or surgery (n = 18), and identify prognostic indicators. Parameters evaluated included: age, weight, gender, presenting complaints, duration of clinical signs, complete blood count, serum biochemistry, neoplasia size, placement of percutaneous endoscopically-placed gastrostomy tube, histopathological mitotic indices, days to discharge and chemotherapy administration. Kaplan-Meier survival curves showed no difference in survival between ablation and surgery {(median: 73.5 days (range: 0-1511) vs. 108 days (range: 0-1550), respectively (p = 0.982)}. Reduced survival was documented in patients presenting with weight loss (P = 0.027), hypochromasia (MCHC <33 g/dL, P = 0.023) or leucocytosis (>15 × 10/L, P = 0.017) with a hazard ratio of 2.51 (CI = 1.071-6.018, P = 0.034), 2.71 (CI = 1.10-6.65, P = 0.03) and 4.39 (CI: 1.21-15.97, P = 0.025) respectively. In the dogs surviving more than 21 days, Ht <36% and leucocytosis >15.0 × 10/L at presentation were associated with reduced survival (p = 0.016, p = 0.021 respectively) and hazard ratio of 3.29 (CI = 1.18-9.2, P = 0.023) and 3.81 (CI = 1.15-12.55, P = 0.028) respectively. Intra-intervention-group survival analysis identified increased survival time in dogs receiving chemotherapy, but only within the surgical group (P = 0.02).The hospitalisation time of dogs undergoing ablation (median: 0 days, range: 0-4) was significantly shorter than dogs undergoing surgery (9 days, 1-21) (P < 0.001). In this study, no clear benefit was identified for surgery, thus when ablation is technically possible it should be considered advantageous, as hospitalisation time is significantly shorter. Weight loss, hypochromasia and leucocytosis were identified as long-term prognostic indicators at presentation.

show abstract

Successful transendoscopic oesophageal mass ablation in two dogs with Spirocerca lupi associated oesophageal sarcoma

Cited by 15 publications

References 24 publications

Long‐term outcome of transendoscopic oesophageal mass ablation in dogs with Spirocerca lupi ‐associated oesophageal sarcoma

Long‐term outcome of transendoscopic oesophageal mass ablation in dogs with Spirocerca lupi ‐associated oesophageal sarcoma

Risk Factors for Development of Canine and Human Osteosarcoma: A Comparative Review

Spirocerca lupi induced oesophageal neoplasia: Predictors of surgical outcome

Contact Info

Product

Resources

About